ClinicalTrials.gg
RecruitingNCT07081555Updated Oct 1, 2025

A First-in-Human Phase 1 Safety and Biodistribution of [177Lu]Lu-ABY-271 in Subjects With HER2-positive Metastatic Breast Cancer

A Phase 1 interventional study of [177Lu]Lu-ABY-271 in Metastatic Breast Cancer and HER2 + Breast Cancer, sponsored by Affibody. Recruiting at 3 sites in Sweden. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-01.

Sponsored by Affibody · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 252 studies in Breast Neoplasms with a site in Sweden — 56 open to participants now, 91 under way, 31 of them phase 3. Breast Neoplasms · Sweden.

Planned enrollment
200th of 209
21 · median 330
Started
2025
with 16 others
Phase 1
5 of 252
1 open now
Primary completion
2027-01
later than 45 of 90 live
Registered
240th of 252
by date

Among the 252 studies in Breast Neoplasms with a site in Sweden, this one is the 200th largest by planned enrollment of the 209 interventional ones that give a count, is one of 17 that started in 2025, is one of 5 in phase 1, reaches primary completion later than 45 of the 90 other live ones, and was the 240th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

56 of the 252 studies in Breast Neoplasms with a site in Sweden are open now. Recruiting first, the newest first:

50 more — sign in →

All 56 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 252 studies in Breast Neoplasms with a site in Sweden, or all of them as a file.
02

Study summary

This is a FiH phase 1, open-label, two-stage, randomized trial to assess the safety, tolerability, and biodistribution of [177Lu]Lu-ABY-271 in subjects with HER2 positive metastatic breast cancer.

Read the detailed description

The trial consists of two parts:

Part A in which the uptake of [177Lu]Lu-ABY-271 in tumors and critical organs will be evaluated and up to 6 subjects will be enrolled sequentially.

Part B in which the optimal protein mass dose range (mg) to be utilized in subsequent clinical trials will be evaluated. 15 subjects will be randomized to 3 different protein mass dose levels (1:1:1), divided into two sequential cohorts with different radioactivity levels.

03

Conditions studied

  • Metastatic Breast Cancer
  • HER2 + Breast Cancer

Browse trials for

Keywords

  • Radiopharmaceutical
  • Biodistribution
  • First-in-human
  • phase 1
  • safety
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has unresectable locally advanced or breast cancer
  • Subject with or cytologically confirmed carcinoma with documented overexpression ( not older than 2 years): immunohistochemistry (IHC) score 3+; OR 2+ and fluorescence in situ hybridization (ISH) positive
  • At least one known tumor lesion ≥ 15 mm
  • (ECOG) performance status ≤ 2

Part A only

- Subject is in treatment, or planned to start a new line of standard systemic anti-tumor therapy

Part B only

  • Subject has progressive disease, documented radiologically in the last three months
  • Subject has received at least 3 lines of standard systemic anti-tumor therapy in the palliative setting
  • Subject has received last dose of previous line of systemic anti-tumor therapy, and has no ongoing treatment related toxicities > grade 1 (except alopecia) prior to planned first dose of [177Lu]Lu-ABY-271

Exclusion criteria

Exclusion Criteria:

  • Active
  • Administration of another IMP within 5 half-lives (for experimental biologics: 6 months or 5 half-lives, whichever is longer) of the planned first dose of [177Lu]Lu-ABY-271
  • Exposure to any anti-tumor therapy since the last documented progression, including any radiotherapy within 7 days prior to the planned first dose of [177Lu]Lu-ABY-271
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
21 participants (estimated)

Study arms

  • Experimental
    Part A

    \[177Lu\]Lu-ABY-271

    Drug: [177Lu]Lu-ABY-271

  • Experimental
    Part B - Cohort 1

    \[177Lu\]Lu-ABY-271 with protein mass dose A

    Drug: [177Lu]Lu-ABY-271

  • Experimental
    Part B - Cohort 2

    \[177Lu\]Lu-ABY-271 with protein mass dose B

    Drug: [177Lu]Lu-ABY-271

  • Experimental
    Part B - Cohort 3

    \[177Lu\]Lu-ABY-271 with Protein mass dose C

    Drug: [177Lu]Lu-ABY-271

Interventions

06

What researchers measure

Primary outcomes

  1. Treatment emergent adverse events

    Time frame: From baseline to the end-of-trial visit, for part A Day 29 and for part B Day 43

  2. Dose Limiting Toxicities

    Time frame: From baseline to the end-of-trial visit, for part A Day 29 and for part B Day 43

Secondary outcomes

  1. Absorbed dose in gray (Gy) per organ and selected tumors

    Time frame: From baseline to day 8

  2. Absorbed dose coefficient (Gy/GBq) per organ and selected tumors

    Time frame: From baseline to day 8

  3. Normalized whole-body effective dose (millisieverts [mSv]/MBq)

    Time frame: From baseline to day 8

07

Study locations

3 of 3 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2025; primary completion for Jan 2027, 14 months later.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's planned 14 months is below that.

Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2025
First posted
Jul 23, 2025
StartEst.
Oct 6, 2025
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jun 1, 2028
Last update
Oct 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07081555
Lead sponsor
Affibody
Responsible party
Sponsor
First posted
Jul 23, 2025
Start date
Oct 6, 2025 (estimated)
Primary completion
Jan 1, 2027 (estimated)
Completion
Jun 1, 2028 (estimated)
Last update
Oct 1, 2025

Study contacts

Affibody AB
Contact
ABY-271-101@affibody.se
46859883800

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lutetium-177

Start the discussion